Navigation Links
Irene Hegeman Richard, MD, Appointed Senior Medical Advisor to The Michael J. Fox Foundation
Date:11/29/2007

NEW YORK, Nov. 29 /PRNewswire-USNewswire/ -- In keeping with The Michael J. Fox Foundation's mission to accelerate scientific breakthroughs that can transform the lives of people with Parkinson's disease, the Foundation today announced the appointment of Irene Hegeman Richard, MD, to the newly created role of Senior Medical Advisor. This appointment formalizes the role of Dr. Richard, who is associate professor of neurology and psychiatry at the University of Rochester School of Medicine and Dentistry, in helping to inform and develop MJFF's clinical agenda.

Dr. Richard brings experience in running large-scale Parkinson's trials and is familiar with the challenges facing this research area. Formalizing her role as advisor to the Foundation will help ensure that MJFF's increasing involvement in clinical trials, including trial design and regulatory issues, is as efficient and targeted as possible. She will also provide important feedback on pre-clinical experimental design, helping to ensure that all studies funded by MJFF --- not only those requiring the active involvement of patients --- are designed with potential clinical issues in mind.

"Irene's clinical research perspective complements the scientific expertise of Gene Johnson, PhD, MJFF's chief scientific advisor, and her input will be a boon to our research staff and advisors in continually raising the bar on the patient-relevant outcomes we expect from every project we fund," said Katie Hood, interim CEO of The Michael J. Fox Foundation. "Additionally, as a clinician with an active neurology practice, Irene has a deep understanding of the challenges faced every day by people living with PD --- something the Foundation values deeply, since patients are at the center of every activity we undertake."

Dr. Richard has served on the Foundation's SAB since 2006. She also has been a member of the review committee for the Foundation's annual Clinical Discovery Program, which funds high-impact clinical projects in PD, since the program was first launched in 2004, and has played a key role in continually refining its specific criteria for patient-relevant grant selection. Additionally, she has frequently spoken to MJFF friends and supporters at the Foundation's Research Roundtable events across the country.

At the University of Rochester, Dr. Richard provides neurological care for people living with PD and runs a research program focused on the psychiatric aspects of the illness. She is currently leading an NIH-funded multi-center clinical trial evaluating the treatment of depression in PD. She has given lectures and chaired workshops and symposia at national meetings including the American Academy of Neurology and The World Parkinson Congress.

"As a grant reviewer for the Foundation and a member of its Scientific Advisory Board, I've been impressed by The Michael J. Fox Foundation's extraordinary commitment to speeding scientific solutions to the clinic and patients --- a commitment I share," said Dr. Richard. "The Foundation understands that it's never too early in the drug development process to think clinically, and I'm thrilled to take on formal responsibility for working with its staff and advisors to continually improve our ability to do this across the board."

About The Michael J. Fox Foundation

Founded in 2000, The Michael J. Fox Foundation for Parkinson's Research is dedicated to ensuring the development of a cure for Parkinson's disease within this decade through an aggressively funded research agenda. The Foundation has funded over $98 million in research to date, either directly or through partnerships.


'/>"/>
SOURCE Michael J. Fox Foundation
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Dr. Allen Woolf Appointed Chief Medical Officer For CIGNA Group Insurance
2. William Moore Appointed to IRIDEX Board of Directors
3. Roy Jakobs Appointed Elsevier Managing Director, A&G Sales and Customer Marketing
4. Katie Hood Appointed Interim Chief Executive Officer of Michael J. Fox Foundation
5. Theodore A. Boutacoff Appointed President & CEO of IRIDEX
6. James B. Hawkins Appointed to IRIDEX Board of Directors
7. Bryan R. Rogers Appointed President of Far West Division
8. Catholic Health Association Disappointed by Failure to Override SCHIP Veto
9. Steven M. Safyer, MD, Appointed President and CEO of Montefiore Medical Center
10. Dr. Warren Wasiewski Appointed Chief Medical Officer of Neurobiological Technologies, Inc.
11. Oral Health a Matter of Life and Death for Seniors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... 2016 , ... Experts from the American Institutes for Research ... June 26-28, 2016, at the Hynes Convention Center in Boston. , AIR experts ... planning, healthcare costs and patient and family engagement. , AIR researchers will be ...
(Date:6/25/2016)... Long Beach, CA (PRWEB) , ... June 25, 2016 , ... ... from UCLA with Magna Cum Laude and his M.D from the David Geffen School ... San Diego and returned to Los Angeles to complete his fellowship in hematology/oncology at ...
(Date:6/24/2016)... ... June 24, 2016 , ... Those who have experienced traumatic events may suffer ... unhealthy avenues, such as drug or alcohol abuse, as a coping mechanism. To avoid ... healthy coping following a traumatic event. , Trauma sufferers tend to feel a range ...
(Date:6/24/2016)... Francisco, CA (PRWEB) , ... June 24, 2016 ... ... CitiDent, is now offering micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has extensive ... self-ligating Damon brackets , AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... ... Living, is proud to recognize Dr. Barry M. Weintraub as a prominent plastic ... most beautiful women in the world, and the most handsome men, look naturally ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... Research and Markets has announced the ... to 2022" report to their offering. ... patients with kidney failure, it replaces the function of kidneys ... blood and thus the treatment helps to keep the patient ... Increasing number of ESRD patients & substantial ...
(Date:6/23/2016)... 2016 Roche (SIX: RO, ROG; OTCQX: RHHBY) ... Elecsys BRAHMS PCT (procalcitonin) assay as a dedicated testing ... With this clearance, Roche is the first IVD company ... for sepsis risk assessment and management. PCT ... PCT levels in blood can aid clinicians in assessing ...
(Date:6/23/2016)... 23, 2016 Bracket , a leading clinical ... generation clinical outcomes platform, Bracket eCOA (SM) 6.0, at ... 26 – 30, 2016 in Philadelphia , ... Outcome Assessment product of its kind to fully integrate with ... Bracket eCOA 6.0 is a flexible platform for electronic clinical ...
Breaking Medicine Technology: